Cambridge Investment Research Advisors, Inc. Clearside Biomedical, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 10,500 shares of CLSD stock, worth $9,135. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,500
Previous 10,500
-0.0%
Holding current value
$9,135
Previous $14,000
7.14%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.47 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$1.91 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.68 Million0.04% of portfolio
-
Black Rock Inc. New York, NY798KShares$694,3790.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$648,0530.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $52.4M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...